JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...

JPMorgan analyst Anupam Rama lowered the firm’s price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the ...

Last Friday, Sage Therapeutics announced the FDA rejected its major depressive disorder drug candidate, zuranolone. In response, the drugmaker's shares cratered Monday. This hefty sell-off may ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

As a result, the stock price has crashed more than 50% in just the past month. Does Sage Therapeutics make for a good contrarian buy, or is the business in real trouble? A big problem with many ...

Ratings for Sage Therapeutics (NASDAQ:SAGE) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE) in the last three months. The following table encapsulates ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

SAGE Therapeutics ( (SAGE)) has shared an announcement. Biogen has informed Sage Therapeutics of its decision to terminate their collaboration on the SAGE-324 molecule, effective February 17 ...